Dyadic International Inc - DYAI Forward Price-to-Revenue Multiple

Dyadic International (DYAI) relies on an academic approach and R&D autonomy to attract microbiologists. The forward price-to-sales valuation trend helps assess cost risks, where the value of 3.30 serves as the current metric. Development is based on establishing partnerships with veterinary corporations, while long-term growth will be driven by the licensing of fungal technology for the low-cost production of biologics and vaccines.

Dyadic International, Inc. - DYAI Forward P/S Multiple (period 07/04/2022 - 11/13/2026)

Analytical breakdowns for Dyadic International

- current price and projected stock value:

Stock Price Dyadic International, Inc.|DYAI - Broker Consensus Forecast

- issuer market value details:

Market Valuation DYAI|DYAI - Total Enterprise Value

- business book valuation details:

Book Value per Share Dyadic International|DYAI - Book Capitalization|Market Capitalization to Book Value Ratio dyadic.com|DYAI - Total Business Assets

- debt and liquidity data:

- financial results and valuation multiples details:

DYAI - Company Profit|Future Profit Dyadic International|DYAI - Market Price to Net Income Ratio|Forward P/E Multiple Dyadic International, Inc.|DYAI - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DYAI|DYAI - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Dyadic International|DYAI - Earnings per share for the last 12 months|Quarterly EPS earnings growth dyadic.com|DYAI - Earnings growth in current year|Expected earnings per share growth for next year Dyadic International

- total revenue and sales volume data:

DYAI - Company Total Sales|Projected Sales Volume Dyadic International, Inc.|DYAI - Price-to-Revenue Coefficient|Price-to-Projected Revenue Ratio DYAI

Analysis of all company metrics:Dyadic (DYAI)

For Dyadic International (DYAI), whose revenue depends on the implementation of protein expression platforms and grants, investment attractiveness is based on projected future cash flows. The projected P/S trend correlates the current share price with expected sales volume, allowing for an assessment of the premium paid for growth potential in the absence of stable operating cash flow.

Key competitors

Forward P/S Multiple GILD (Gilead Sciences)|CDTX: Market Cap to Projected Revenue|NVAX: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio CureVac Pharma|VALN: Forward P/S Multiple|vir.bio (VIR) - Forward P/S Multiple|SIGA (SIGA Technologies) - Forward P/S Multiple|Market Cap to Projected Revenue EBS (Emergent BioSolutions Inc)|Forward P/S Multiple AVIR|Market Cap to Expected Sales Ratio invivyd.com|Forward P/S Multiple ENTA (Enanta Pharmaceuticals)|INO - Forward Price-to-Revenue Multiple|HLVX: Forward Price-to-Revenue Multiple|Forward Price to Sales KLRS (Kalaris Therapeutics Inc.)|NNVC: Forward P/S Multiple|TLPH - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Cocrystal Pharma, Inc.|Market Cap to Projected Revenue TRAW (Traws Therapeutics)|Forward Price-to-Revenue Multiple DWTX (Dogwood Therapeutics, Inc.)|Price to Expected Revenue Ratio QLGN|Forward P/S Multiple ALVR (AlloVir)|VBI Vaccines, Inc. (VBIV) - Market Cap to Future Revenue Ratio|VIRI - Price-to-Projected Revenue Ratio|Forward Price to Sales VXRT (Vaxart, Inc.)